Ventolin, Serevent, Flovent Diskus recall

Several Diskus dry powder inhalers used in the treatment of asthma and chronic obstructive pulmonary disease are being recalled because they were manufactured incorrectly and may fail to deliver therapeutic drug doses.1 Specific lots of Ventolin, Serevent and Flovent Diskus products (Table 1) are affected by the defect, which occurs in less than 0.18% of the devices. Although Diskus products approved by the US Food and Drug Administration (FDA) for sale in the United States (Advair and Serevent) are not affected by the recall, the FDA has alerted American consumers about the Canadian recall because they may have obtained prescription drugs from Canada and elsewhere through online or storefront operations.2

Blue dye test: toxicities include blue discoloration and death

The dve FD&C Blue No. 1 (Blue 1; triphenylmethane) is sometimes added to enteral feeding solutions of critically ill patients to detect pulmonary aspiration. However, serious outcomes have been reported in some patients undergoing such tests. The FDA recently

Table 1: Recalled Diskus products

Diskus product	Affected lots	Range of expiry dates
Ventolin 200 μg	073, 081, 094, 105	Apr to Nov 2004
Serevent 50 μg	491, 496, 527, 537, 550, 556	June 2004 to Jan 2005
Flovent 50 µg	122, 138, 146	Dec 2003 to July 2004
Flovent 100 µg	346, 397	Jan to Apr 2004
Flovent 250 µg	305, 325, 347, 354, 356, 360, 375	Dec 2003 to July 2004
Flovent 500 µg	579, 600, 605, 608, 614, 615	Dec 2003 to June 2004

issued a warning that the test may result in rare but serious toxic effects, including bluegreen discoloration of the skin and bodily fluids, refractory hypotension, metabolic acidosis and death.3

Blue 1 is a water-soluble dye used in a variety of foods and drugs because it is relatively nontoxic and poorly absorbed systemically at daily doses in the range of 12 mg/kg body weight.3 Unfortunately, many critically ill patients may have altered gastrointestinal permeability, in which case more of the dye would be absorbed systemically. In vitro the dye causes mitochondrial toxicity, which may be the mechanism behind many of the serious reported adverse effects.

Certain critically ill patients with altered gut permeability, such as those with sepsis, burns, shock, trauma, surgical interventions, renal failure, celiac sprue or inflammatory bowel

disease, may be at increased risk of toxic effects from the blue dye test. The practicality and safety of different tests (e.g., glucose monitoring in secretions) and other blue dyes (methylene blue and FD&C Blue No. 2) is not yet clear.

Eric Wooltorton CMA7

References

- Important safety information regarding the recall of Ventolin® Diskus® / Serevent® Diskus® / Flovent® Diskus® [Dear Health Care Professional Letter]. Mississauga (ON): GlaxoSmithKline Inc.; 2003 Nov 10. Available: www.hc-sc.gc.ca /hpfb-dgpsa/tpd-dpt/diskus_hpc_e.html (accessed 2003 Dec 1).
- FDA alerts U.S. residents to recall of GlaxoSmithKline "Diskus" asthma medicines sold in Canada. Washington: US Food and Drug Administration; 2003 Nov 14. Available: www.fda.gov/bbs /topics/ANSWERS/2003/ANS01261 .html (accessed 2003 Dec 1).
- Reports of blue discoloration and death in patients receiving enteral feedings tinted with the dye, FD&C Blue No. 1. Washington: US Food and Drug Administration; 2003 Sept 29. Available: www.cfsan .fda.gov/%7Edms/col-ltr2.html (accessed 2003 Dec 1).

Canadian Adverse Reaction Newsletter Bulletin canadien des effets indésirables

To receive the Newsletter and health product Advisories by email, join Health Canada's Health_Prod_Info mailing list. Go to www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/subscribe_e.html.

Inscrivez-vous à la liste Info_Prod_Santé de Santé Canada pour recevoir par courriel le Bulletin et les Avis au sujet des produits de santé. Rendez-vous à l'adresse www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/subscribe f.html.

> Report adverse reactions toll free to Health Canada Signaler sans frais des effets indésirables à Santé Canada

Tel./Tél.: 866 234-2345 • Fax/Téléc.: 866 678-6789



Santé

Email/Courriel: cadrmp@hc-sc.gc.ca

Canada